Luyckx A, Daubresse JC, Carpentier JL, Lefèbvre P, La place des biguanides dans le traitement du diabète sucré. Journées Annuelles de Diabétolagie de l'Hôtel-Dieu. Paris ; Flammarion, 1974 : 129-54.
Hermann LS, Melander A. Biguanides : Basic aspects and clinical uses. In : Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, editors, International Textbook of Diabetes Mellitus. Chichester : J. Wiley, 1992 : 773-95.
Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992 ; 15 : 755-72.
Dunn CJ, Peters DH, Metformin. A Review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995 ; 49 : 721-49.
DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus : The Multicenter Metformin Study Group. N Engl J Med 1995 ; 333 : 541-9.
Bailey CJ, Turner RC. Metformin. N Engl J Med 1996 ; 334 : 574-9.
Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997 ; 102 : 99-110.
Scheen AJ, Lefèbvre PJ, La metformine : des effets métaboliques aux indications rhérapeutiques. Méd et Hyg 1993 ; 51 : 1993-8.
Sirtori CR, Pasik C. Reevaluation of a biguanide. metformin : Mechanism of action and tolerability. Pharmacol Research 1994 ; 30 : 187-228.
Andreani D, Lefèhvre P, editors. Metformin : Mechanisms of action and clinical use. Diabetes Metab Rev 1995 ; II (Suppl. 1) : S1-S108.
Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe. A concensus view. Diabetic Med 1988 ; 5 : 275-81.
American Diabetes Association. Consensus Statement. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995 ; 18 : 1510-8.
Lefèbvre PJ, Scheen AJ. Management of non-insulin-dependent diabetes mellitus. Drugs 1992 ; 44 (Suppl. 3) : 29-38.
DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991 ; 73 : 1294-301.
Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994 ; 43 : 920-8.
Hermann LS, Scherstén B, Bitzén P-O. et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994 ; 17 : 1100-9.
Widen EIM, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992 ; 41 : 354-8.
Fendri S, Debussche X, Puy H, et al. Metformin effects on peripheral sensitivity to insulin in non diabetic obese subjects. Diabete Metab 1993 ; 19 : 245-9.
Scheen AJ, Letiexhe MR, Lefèbvre PJ. Effects of metformin in obese patients with impaired glucose tolerance Diabetes Metab Rev 1995 ; 11 : S69-S80.
Scheen AJ, Letiexhe MR, Lefèbvre PJ. Short administration of metformin improves insulin sensitivity in obese android subjects with impaired glucose tolerance. Diabetic Med 1995 ; 12 : 985-9.
Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformen reduces both blood pressure and metabolic risk factors. J Internal Med 1991 ; 229 : 181-7.
Giugliano D, De Rosa N, Di Maro G. et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993 ; 16 : 1387-90.
Vague Ph, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987 ; 57 ; 326-8.
Grant PJ. The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. Diab Metab 1991 ; 17 : 168-73.
Fontbonne A, Charles MA, Juhan-Vague I. et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996 ; 19 : 920-6.
Scheen AJ, Paquot N, Castillo MJ, Lefèbvre PJ. Traitement du diabète de type II insulino-requérant : intérèt potentiel de l'association insuline-antidiabétiques oraux. Méd et Hyg 1996 ; 54 : 1470-1.
Slama G. The insulin sparing effect of metformin in insulin treated diabetic patients. Diab Metab 1991 ; 17 : 241-3.
Golay A, Guillet-Dauphiné N, Fendel A, et al. The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev 1995 ; 11 (Suppl. 1) : S63-7.
Giugliano D, Quatraro A, Consoli G. et al. Metformin for obese, insulin-treated diabetic patients : Improvements in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993 ; 44 :107-12.
Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokin 1996 ; 30 : 359-71.
Chalmers J, McBain AM, Brown IRF, et al. Metformin : Is it use contraindicated in the elderly ? Practical Diabetes 1992 ; 9 : 51-3.
Knight PV, Semple CG, Kesson CM. The use of metformin in the older patient. J Clin Exp Geront 1986 ; 8 : 51-8.
Gregorio F, Ambrosi F, Filipponi P. et al. Is metformin safe enough for ageing type 2 diabetic patients ? Diab Metab 1996, 22 : 43-50.
Lalau JD, Vermersch A, Hary L. et al. Type 2 diabetes in the elderly : An assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990 ; 28 : 329-3.
Giugliano D, Luyckx A, Binder D, Lefèbvre P. Comparative effects of metformin and indanore in the treatment of reactive hypoglycemia. Int J Clin Pharmacol 1979 ; 17 : 76-81.
Gerard J, Luyckx AS, Lef̀bvre PJ. Acarbose in reactive hypoglycemia : A double-blind study. Int J Clin Pharmacol Ther Toxicol 1984 ; 22 : 25-31.
Lefèbvre PJ, Scheen AJ. The use of acarbose in the prevention and treatment of hypoglycaemia. Eur J Clin Invest 1994 ; 24 (Suppl. 3) : 40-4.
